Keyphrases
Improved Survival
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Cumulative Incidence
50%
Therapeutic Potential
25%
Second-line Therapy
25%
Tumor Classification
25%
Patient Survival
25%
Specific Antigen
25%
Prolonged Life
25%
Surgical Castration
25%
Endocrine Therapy
25%
New Agents
25%
Overall Survival
25%
Delayed Diagnosis
25%
Life-sustaining Treatment
25%
Comorbidity
25%
Specific Survival
25%
Median Overall Survival
25%
Medicine and Dentistry
Prostate Cancer
100%
Cumulative Incidence
50%
Overall Survival
50%
Population Research
25%
Neoplasm
25%
Antigen Specificity
25%
Life Sustaining Treatment
25%
Comorbidity
25%
Hormone Therapy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Overall Survival
50%
Endocrine Therapy
25%
Neoplasm
25%
Population Study
25%
Comorbidity
25%
Nursing and Health Professions
Prostate Cancer
100%
Overall Survival
50%
Comorbidity
25%
Hormonal Therapy
25%
Life Sustaining Treatment
25%
Neoplasm
25%